ClinicalTrials.gg
RecruitingNCT07098858Updated Oct 16, 2026

The WiSE®-UP Study (The WiSE System Utilization & Performance Study)

An observational study in Heart Failure, sponsored by EBR Systems, Inc.. Recruiting at 12 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by EBR Systems, Inc. · Observational

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Updated Oct 16, 2026Site recruiting status changedStudy contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
320
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,159 studies in Heart Failure with a site in United States — 346 open to participants now, 439 under way, 27 of them phase 3. Heart Failure · United States.

Planned enrollment
206th of 552
320 · median 150
Started
2025
with 107 others
Observational
553 of 2,159
102 open now
Primary completion
2032-09
later than 428 of 438 live
Registered
2,032nd of 2,159
by date

Among the 2,159 studies in Heart Failure with a site in United States, this one is the 206th largest by planned enrollment of the 552 observational ones that give a count, is one of 108 that started in 2025, is one of 553 observational ones, reaches primary completion later than 428 of the 438 other live ones, and was the 2,032nd registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

346 of the 2,159 studies in Heart Failure with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,159 studies in Heart Failure with a site in United States, or all of them as a file.
02

Study summary

Observe to understand product performance, including patient safety, clinical outcomes, and CRT response information associated with the use of the market-released WiSE System

Read the detailed description

The WiSE-UP Study is a prospective, real-world, observational study aimed at understanding acute and long-term product performance, including patient safety, clinical outcomes, and CRT response information associated with the use of the market-released WiSE System.

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Up to 320 patients will be enrolled in the study and followed for five years.

Eligibility criteria

  • Patient or legally authorized representative can provide written authorization and/or consent per institution requirements.
  • Patient is intended to receive a WiSE System and passed the acoustic window screening
  • Patient who is, or will be, accessible for follow-up.
  • Participation is not excluded by local law.
  • Patient is not enrolled in a concurrent drug and/or device study that may confound the Registry results.
  • Patient >1 year.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
320 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Single-arm, prospective, multicenter, observational study.

    Market-released WiSE System approved for commercial release with a market-released co-implanted system are eligible.

    Device: The Wise System

Interventions

  • DeviceThe Wise System

    The WiSE CRT System is an implantable cardiac system to provide left ventricular (LV) pacing stimulation in conjunction with a co-implanted system that provides right ventricular (RV) stimulation. In combination, the devices deliver biventricular (BiV) pacing.

06

What researchers measure

Primary outcomes

  1. Primary Safety

    The primary outcome measure of the Study is the rate of serious adverse events (SAEs) at \< 30 days post implant related to the WiSE System and/or implant procedure.

    Time frame: 1, 6, 12, 24, 48 and 60 months

Secondary outcomes

  1. Efficacy 1

    Procedural Success of the Leadless LV endocardial pacing (LVEP)

    Time frame: 1 month

  2. Efficacy 2

    CRT response assessment of NYHA functional classification

    Time frame: 1 month

  3. Efficacy 3

    Left ventricular ejection fraction (LVEF)

    Time frame: 6 months

  4. Efficacy 4

    Left ventricular and systolic volume (LVESV)

    Time frame: 6 months

  5. Efficacy 5

    Heart failure clinical composite score (HF CCS) categorizing patients as improved, unchanged or worsened

    Time frame: 1, 6, 12, 24, 48 and 60 months

  6. Efficacy 6

    New York Heart Association (NYHA) classification values of Markedly improved, Moderately improved, Mild improvement, No change or Slightly worse

    Time frame: 1, 6, 12, 24, 48 and 60 months

  7. Efficacy 7

    QRS duration

    Time frame: 1, 6, 12, 24, 48 and 60 months

  8. Efficacy 8

    Minnesota Living with Heart Failure Questionnaire (MLHFQ) a validated tool designed to assess the impact of heart failure on a patient's quality of life

    Time frame: 6 and 12 months

  9. Efficacy 9

    Events assessment: confirmation of reportable events including updates to any previously reported events

    Time frame: 1, 6, 12, 24, 48 and 60 months

  10. Efficacy 10

    Mortality is based on an estimated 1-year rate of 10%- and 1-year attrition of up to 15%

    Time frame: 1, 6, 12, 24, 48 and 60 months

  11. Efficacy 11

    Patient global assessment

    Time frame: 1, 6, 12, 24, 48 and 60 months

07

Study locations

12 of 12 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Sep 2032, 82 months after the start.

Of 183 industry-sponsored observational studies under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 57. This study's planned 82 months is above that.

Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2025
First posted
Aug 1, 2025
StartActual
Nov 3, 2025
Primary completionEst.
Sep 30, 2032
CompletionEst.
Sep 30, 2032
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
CardioVascular Associates of Mesa (CVAM) is now Recruiting
Oct 16, 2026
Contact
Study contact's phone or email changed: •••4185→•••1906. See the current contact
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    CardioVascular Associates of Mesa (CVAM) is now Recruiting
    Contact Study contact's phone or email changed: •••4185→•••1906. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07098858
Lead sponsor
EBR Systems, Inc.
Responsible party
Sponsor
First posted
Aug 1, 2025
Start date
Nov 3, 2025
Primary completion
Sep 30, 2032 (estimated)
Completion
Sep 30, 2032 (estimated)
Last update
Oct 16, 2026

Study contacts

Jamie Burke
Contact
clinical@ebrwise.com
408-720-1906

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion